We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CIDP

News List

Pfizer gets US FDA approval for PANZYGA to treat chronic inflammatory demyelinating polyneuropathy expresspharma
February 18, 2021
t is the only FDA-approved intravenous immunoglobulin with two maintenance dosing options for CIDP.
US nod for CSL Behring’s Hizentra pharmatimes
July 23, 2018
US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.
FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patien biospace
March 19, 2018
CSL Behring today announced that FDA approved Hizentra®as the first and only SCIg for the treatment of CIDP as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
CSL Behring announces FDA approval of Privigen for the treatment of CIDP in adults biospectrumasia
September 18, 2017
The FDA approval was based on results from two Phase III clinical studies that focused on the use of immunoglobulin (Ig) therapy for treating CIDP – the Polyneuropathy and Treatment with Hizentra (PATH) study